Elan big ISEQ mover on painkiller trial success

Irish pharmaceutical giant Elan saw its share price advance 57c to €5.97 on the ISEQ today as news of its intention to launch a new painkiller to the US market by Spring 2005 reached the market.

The company reported positive results after Phase III clinical trails for its ‘Prialt’ product proved successful. Prialt will be available on a limited basis to select pain centres in the US from Q1 2004.